Allogene cell therapy trials halted by FDA after safety finding

The Food and Drug Administration has halted testing for a group of cancer cell therapies from Allogene Therapeutics after a "chromosomal abnormality" was observed in a single patient who received one of the treatments, the biotech said in an announcement Thursday afternoon.